Literature DB >> 30555740

The role of adrenergic receptors in lung cancer.

Qi Huang1, Qi Tan1, Kaimin Mao1, Guanghai Yang2, Guangzhou Ma1, Ping Luo3, Sufei Wang1, Peiyuan Mei2, Feng Wu1, Juanjuan Xu1, Mengfei Guo1, Zhilei Lv1, Jinshuo Fan1, Shuai Zhang1, Xuan Wang1, Yang Jin1.   

Abstract

Adrenergic receptors (ARs), especially β-ARs, are constitutively expressed in most mammalian cells and are associated with various malignancies including lung cancer. Epidemiologic studies have reported that activation of β-AR signalling promotes the development and progression of lung cancer and that pharmacological interference by β-AR blockers could partially reverse lung cancer progression. In this review, we mainly focus on the role of β-ARs in lung cancer and then reveal the possible application of AR blockers in anti-tumour therapy for lung cancer.

Entities:  

Keywords:  ADRB2; β-adrenergic receptor; β-adrenergic receptors

Year:  2018        PMID: 30555740      PMCID: PMC6291649     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  9 in total

Review 1.  The role of ADRB2 gene polymorphisms in malignancies.

Authors:  Yaqian Wang; Shujuan Jiang
Journal:  Mol Biol Rep       Date:  2021-03-06       Impact factor: 2.316

2.  Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.

Authors:  Mengqing Chen; Xue Wang; Wenjun Wang; Xuemei Gui; Zhan Li
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

Review 3.  Glycosylation and raft endocytosis in cancer.

Authors:  Ludger Johannes; Anne Billet
Journal:  Cancer Metastasis Rev       Date:  2020-06       Impact factor: 9.264

Review 4.  Anabolic and Pro-metabolic Functions of CREB-CRTC in Skeletal Muscle: Advantages and Obstacles for Type 2 Diabetes and Cancer Cachexia.

Authors:  Rebecca Berdeaux; Chase Hutchins
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

5.  Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors.

Authors:  Yingzhuo Xu; Jian Wang; Xu Wang; Xiaoshu Zhou; Jing Tang; Xiaohua Jie; Xijie Yang; Xinrui Rao; Yunhong Xu; Biyuan Xing; Zhenyu Li; Gang Wu
Journal:  Cell Death Discov       Date:  2022-01-24

6.  ADRB2 expression predicts the clinical outcomes and is associated with immune cells infiltration in lung adenocarcinoma.

Authors:  Lingyun Ji; Fei Xu; Jingtao Zhang; Ting Song; Weida Chen; Xi Yin; Qingqing Wang; Xiubao Chen; Xin Li; Minghao Guo; Zetao Chen
Journal:  Sci Rep       Date:  2022-09-26       Impact factor: 4.996

7.  β3-Adrenoceptors as Putative Regulator of Immune Tolerance in Cancer and Pregnancy.

Authors:  Maura Calvani; Annalisa Dabraio; Angela Subbiani; Daniela Buonvicino; Veronica De Gregorio; Sara Ciullini Mannurita; Alessandro Pini; Patrizia Nardini; Claudio Favre; Luca Filippi
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

Review 8.  The molecular mechanism of chronic stress affecting the occurrence and development of breast cancer and potential drug therapy.

Authors:  Hui-Min Liu; Le-le Ma; Chunyu Li; Bo Cao; Yifang Jiang; Li Han; Runchun Xu; Junzhi Lin; Dingkun Zhang
Journal:  Transl Oncol       Date:  2021-12-04       Impact factor: 4.243

Review 9.  Anesthesia Techniques and Long-Term Oncological Outcomes.

Authors:  Maria F Ramirez; Juan P Cata
Journal:  Front Oncol       Date:  2021-12-08       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.